Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 33


Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.

McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G.

J Clin Oncol. 2009 Sep 1;27(25):4047-54. doi: 10.1200/JCO.2008.19.9968. Epub 2009 Jul 27.


Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?

Caire AA, Sun L, Ode O, Stackhouse DA, Maloney K, Donatucci C, Mouraviev V, Polascik TJ, Robertson CN, Albala DM, Moul JW.

Urology. 2009 Sep;74(3):643-7. doi: 10.1016/j.urology.2009.02.049. Epub 2009 Jun 7.


Cancer statistics, 2009.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ.

CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.


Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen.

Rahrmann EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, Huang W, Largaespada DA, Marker PC.

Cancer Res. 2009 May 15;69(10):4388-97. doi: 10.1158/0008-5472.CAN-08-3901. Epub 2009 Apr 28.


Clinical significance of ABCB1 genotyping in oncology.

Hamidovic A, Hahn K, Kolesar J.

J Oncol Pharm Pract. 2010 Mar;16(1):39-44. doi: 10.1177/1078155209104380. Epub 2009 Apr 28.


An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.

Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B, Toner GC.

Am J Clin Oncol. 2009 Aug;32(4):338-41. doi: 10.1097/COC.0b013e31818b946b.


K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.


Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors.

Kolesar J, Huang W, Eickhoff J, Hahn K, Alberti D, Attia S, Schelman W, Holen K, Traynor A, Ivy P, Wilding G.

Cancer Chemother Pharmacol. 2009 Jun;64(1):79-86. doi: 10.1007/s00280-008-0845-0. Epub 2008 Oct 22.


Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis.

Warren M, Twohig M, Pier T, Eickhoff J, Lin CY, Jarrard D, Huang W.

Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):23-30. doi: 10.1097/PAI.0b013e31817c3334.


Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group.

J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487.


Trastuzumab--mechanism of action and use in clinical practice.

Hudis CA.

N Engl J Med. 2007 Jul 5;357(1):39-51. Review. No abstract available.


A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer.

Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G.

Clin Cancer Res. 2005 Sep 15;11(18):6625-33.


Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.

Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS.

J Mol Diagn. 2005 Aug;7(3):413-21.


Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.

Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW.

Cancer. 2004 Oct 1;101(7):1569-74.


The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial.

Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED.

Prostate. 2004 Sep 1;60(4):332-7.


Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.

Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E.

J Cancer Res Clin Oncol. 2004 Oct;130(10):604-14. Epub 2004 Jul 16.


Laser-capture microdissection: applications in routine molecular dermatopathology.

Yazdi AS, Puchta U, Flaig MJ, Sander CA.

J Cutan Pathol. 2004 Aug;31(7):465-70. Review.


Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.


ErbB receptors: possible therapeutic targets in prostate cancer?

Ratan HL, Gescher A, Steward WP, Mellon JK.

BJU Int. 2003 Dec;92(9):890-5. Review. No abstract available.


The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM.

Mol Cancer Ther. 2001 Dec;1(2):85-94.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk